Introduction
Angiotensin converting enzyme (ACE) is a dipeptidyl carboxypeptidase I, (EC. 3.4.15.1) that activates angiotensin I through cleavage of the carboxyterminal dipeptide into the potent vasoconstrictor angiotensin II and inactivates the vasodilator peptide bradykinin (Erdös and Skidgel, 1987) . Both are mediators of vascular tone and smooth muscle cell proliferation (Ehlers and Riordan, 1989) . Experimental data suggest that the presence of high levels of plasma ACE could result in the thickening of the vascular wall eventually leading to the development of vascular disease (Erdös and Skidgel, 1987; Ehlers and Riordan, 1989) .
Circulating ACE levels show extensive inter-individual variability and are highly genetically determined (Cambian et al., 1988; Alhenc-Gelas et al., 1991) . An insertion/deletion (I/D) dimorphism, due to the presence or absence of a 287 base pair (bp) alu-type sequence in intron 16 of the ACE gene, has been shown to cosegregate with serum and tissue ACE activities, and major locus inheritance explains best the findings that the D allele is associated with elevated ACE levels (Cambian et al., 1988; Rigat et al., 1990; Alhenc-Gelas et al., 1991) . Thus, the ACE gene is viewed as a quantitative trait locus (QTL) that modulates circulating ACE levels, and the ACE I/D dimorphism is a marker that is thought to be in linkage disequilibrium (LD) with functional variants located in the ACE gene (Cambian et al., 1992; Tiret et al., 1992; Arca et al., 1998) that are implicated in CVDs.
Several studies on the association of ACE I/D polymorphism and the risk for myocardial infarction (MI) (Bohn et al., 1993; Cambien et al., 1994; Evans et al., 1994; Soubrier and Cambien, 1994; Cambian and Evans, 1995; Lindpainter et al., 1995; Ferrieres et al., 1999; O' Mally et al., 1999; Keavney et al., 2000) , have generated inconAssociation study of the angiotensin-converting enzym e (ACE) gene G2350A dim orphism with m yocardial infarction sistent information. This has stimulated a search for new polymorphisms in the ACE gene to identify better markers or actual functional variants. Accumulated evidence points to the existence of two QTLs at this chromosomal locus (McKenzie et al., 1995; Zhu et al., 2000; McKenzie et al., 2001) . A genome-scan analysis by The Framingham Heart Study found strong evidence for a QTL on chromosome 17, located close to the ACE gene and linked to blood pressure (Levy et al., 2000) . Amongst the 13 polymorphisms of the ACE gene recently reported, a dimorphism in exon 17, ACE G2350A, has the most significant effect on plasma ACE concentrations (Zhu et al., 2001) . After adjustment for the effect of ACE G2350A dimorphism, the I/D dimorphism was no longer associated with ACE, indicating that it is in LD with ACE G2350A and unlikely to be a functional mutation (Zhu et al., 2001) .
To assess the value of genotyping of ACE in Pakistani population, we carried out a case-control study of dimorphism G2350A for a putative association with MI and with plasma/serum levels of homocysteine and folate amongst Pakistani nationals. Our study is aimed at establishing whether the ACE G2350A dimorphism is a genetic marker and an independent risk factor for MI.
M aterials and M ethods
Study subjects Two hundred and seven consecutive Pakistani patients with acute MI (AMI) (age, 30-70 years) admitted to the National Institute of Cardiovascular Diseases (NICVD), Karachi from January 2001 to June 2001, were selected for this study. They had confirmed diagnosis of AMI on the basis of clinical history, ECG and biochemical data.
Similarly, 163 normal healthy subjects who had been matched for sex and to some extent for age and belonged to the same socio-economic class, were selected from the personnel of the Aga Khan University and Civil Hospital, Karachi for this study. Informed consent was obtained from the participants and the study was approved by the Ethical Committee of the Aga Khan University.
A stringent criteria was used for the selection of normal healthy control subjects. In addition to being matched for age, sex and socioeconomic background, they had no evidence of CAD, diabetes mellitus, hypertension, obesity and hypercholesterolemia. Those control subjects who were found to be pregnant, using antiepileptics, oral contraceptives, having malabosorption syndrome, suffering from tuberculosis, uremia, liver disease, or using B-complex vitamins during the last six months were excluded from this study.
DNA analysis
Blood was collected in 10 m; Na-EDTA tubes and kept frozen at -20 o C. DNA was extracted using standard protocols (Sambrook et al., 1989) and stored in 10 mM Tris-HCl, 1 mM EDTA, pH 8.0.
Codon 2350 ACE genotypes were first visualized by a method based on allele-specific oligonucleotides (McKenzie et al., 1995) . It was then described as ACE-8 by Zhu et al. (2001) , as a modification by introducing a mismatch guanine at the 3' end of the primer sequence, resulting in the amplification of a BstU1 restriction site. This more convenient method involves a set of primers designed to amplify a 122-bp fragment encompassing the polymorphic region of ACE gene: 5'-CTGACGAATGTGATGGCCGC 3' (upstream) and 5'-TTGATGAGTTCCACGTATTTCG-3' (downstream). The PCR contained 100 to 200 ng DNA template, 125 µ M dNTPs, 2.5 mM MgCl2, and 0.3 mM of each primer and 1 U Taq polymerase, in a final volume of 10 µl. After initial denaturation at 95 o C for 5 min, PCR was carried out for 35 cycles, each one comprised of denaturation at 94 o C for 30 s, annealing at 58 o C for 30 s, and extension at 72 o C for 30 s, with a final extension time of 10 min at 72 o C. PCR products (5 µl) were digested with 5 U of BstUI (Life Technologies) at 60 o C for 2 h. Digested fragments were separated by electrophoresis on 3% agarose gel and identified by ethidium bromide staining. Allele G2350 was visualized as a 122-bp fragment and allele A2350 as 100-bp and 22-bp fragments.
Data analysis
Statistical analyses were done with the help of an SPSS version 10.0 for Windows software package (Gorinchem, The Netherlands). Distribution differences of G/A 2350 genotypes in the patients (AMI) as compared to distribution in the control group as well as Hardy-Weinberg proportions of allele distribution were assessed by chi-square analyses on 3×2 tables. Means were compared using ANOVA. For all analyses, statistical significance was considered when significance level (P) values were lower than 0.05.
R esults
Demographic and clinical characteristics of patients have been listed in Table 1 . The patient group comprised 51 females and 156 males, showing a female to male ration of 1:3. The mean age was 53± 9.6 years (range 30-70 years) in this group. Mean body mass index (BMI) was 24±5.6, while mean serum glucose concentration was 144±72 mg/dl. Mean cholesterol concentration was 185±45 mg/dl. 43% of them were smokers, 31% were hypertensive, 57% were diabetic, while 19% were hypercholesterolemic. 26% of the patients had parental history of ischemic heart disease (IHD).
Among the controls, the mean age was 49.3±9.6 years (range 31-70 years). There were 123 males and 40 females and the mean BMI for this group was 24 ±5.6 which was quite close to the mean BMI of cases. 17% of the controls were smokers. 15% of the control subjects had parental history of IHD. Table 2 shows the data pertaining to both genotype and allele distributions in the two groups of subjects. ACE genotypes did not occur in Hardy-Weinberg proportions in the normal control group (χ 2 = 5.82, 2 degrees of freedom (df), P = 0.054) nor in AMI patients (χ 2 = 0.90, 2 df, P = 0.64). Differences in the distributions of the three genotypes according to clinical phenotype were not statistically significant (AMI vs Controls: χ 2 = 3.1, 2 df, P = 0.217). We also sought to explore association of 2350 G A genotypes (GG, GA, AA) with several phenotypic variables including age, BMI, serum folate and plasma homocysteine. There was no significant difference between the age and BMI profiles of the three genotypes (Table 3) . The homocysteine and serum folate values were also not statistically different between genotypes (Table 3) .
D iscussion
Association (retrospective case-control) studies are influenced by the effects of selection bias, population stratification, confounding by other variables, and clinical criteria used to define patient groups. Minimizing the influence of the first two variables can be achieved by the exploration of putative associations in various ethnic groups that may be more genetically homogenous.
Pakistani people belong to an ethnic group which is relatively homogeneous and has the high rates of coronary artery disease CAD (McKeigue et al., 1988) . Moreover, the relative risk of CAD in South Asian men is the highest at early ages (Balerajan, 1991; McKeigue, 1992) . This points to an increased genetic predisposition of this population to the development of CAD.
"Control" individuals that were included in this investigation constituted a "comparison" rather than a "control" group. They were indeed free of disease, sex-matched with the patients, and had similar socioeconomic background to that of the patients. As these control individuals had no evidence of MI, they represented a valid comparison group for these association studies, though it could not be predicted whether some of them would develop MI in future.
Several studies have suggested that the D allele of ACE insertion/deletion (I/D) dimorphism confers increased risk for CVD . At the same time, considerable negative evidence exists on this question. An analysis of 11,000 cases and controls showed no relationship between MI and the I/D polymorphism (Evan et al., 1994) . The I/D marker was likewise not associated with MI in Italian and French sample populations (Arca et al., 1998; Ferrieres et al., 1999) . O'Malley et al. (1999) summarized the association between the I/D polymorphism and CVD risk, grouping studies by geographical region and disease prevalence. In this analysis the ACE I/D polymorphism did not appear to be a clinically useful indicator of risk for MI. Zhu et al. (2001) reported 13 polymorphisms in the ACE gene using linkage and association studies. The polymorphism in exon 17, ACE G2350A had the most significant effect on plasma ACE concentration, accounting for 19% of the total variance in ACE plasma levels. After adjustment for the effect of ACE G2350A dimorphism, the I/D polymorphism was no longer associated with plasma ACE concentration, indicating that it is in LD with ACE G2350A and unlikely to be a functional mutation. Besides the effect on plasma ACE concentration, Zhu et al. (2001) reported that this dimorphism was significantly associated with SBP with an average increase of 3.2 mmHg with each copy of the G allele. These observations were suggestive of a possible role of ACE G2350A polymorphism in MI.
We report the allele frequency of the ACE G2350A polymorphism in the Pakistani population to be 0.68± 0.04 and 0.32±0.04 for the G2350 and A2350 alleles respectively. In the present study, G2350A genotype distributions were not in Hardy-Weinberg proportions in the control group nor in the MI patient group. This may be a direct effect of consanguinity in this population.
Our data on the Pakistani population did not show any significant association between G2350A polymorphism and MI. A recent study from our laboratory, reported a significant association between G2350A polymorphism and essential hypertension in Emirati population (Mahmood et al., 2003) , indicating that this polymorphism may be the functional mutation of the ACE gene. However, no association of G2350A polymorphism was found with MI in Emirati population. Hyperhomocysteinemia has been an established risk factor MI. A recent report by Westphal et al. indicated that ACE inhibitors increase the plasma levels of homocysteine in hypertensive patients, thereby compromising to some extent the cardio-protective function usually associated with them (2003) . This was also suggestive of a possible interaction between ACE gene expression and plasma level of homocysteine. Whether a polymorphic change in the ACE gene could have any influence on plasma homocysteine level is unknown, therefore, we investigated whether there is any association between plasma levels of homocysteine and ACE G2350A polymorphism. Although we found decreased levels of plasma homocysteine in AA genotype (Table 3) , the value was not significantly different from the values in GG and GA genotypes. This is suggestive of no association between any of the three genotypes and plasma levels of homocysteine. Similarly, no association was observed between any of these three genotypes and serum folate levels.
In summary, our data support that the G2350A dimorphism is neither associated with MI nor with plasma homocysteine or folate in the Pakistani population. Given the complex nature of genetic susceptibility for chronic degenerative diseases, further studies need to be conducted in individual ethnic groups to verify the disease relevance of this polymorphism.
